insights_auto
Sebab DMYD-B menurun 2.33%?
Terokai Dengan Lebih Terperincichevron_right
DMYD-B:STO
Diamyd Medical AB
SEK 0.92
arrow_downward
-2.33%(-0.022) 1H
13 Nov, 5:29:52 PTG GMT+1 · SEK
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk DMYD-B...
Buka
SEK 0.91
Tinggi
SEK 0.95
Rendah
SEK 0.90
Permodalan Pasaran
139.51J
Purata volum
550.26K
Volum
0.00
tgi 52 mgu
SEK 17.88
rdh 52 mgu
SEK 0.90
EPS
-SEK 1.76
Syer tertunggak
134.00J
Bilangan pekerja
42
Buka
SEK 0.91
Tinggi
SEK 0.95
Rendah
SEK 0.90
Permodalan Pasaran
139.51J
Purata volum
550.26K
Volum
0.00
tgi 52 mgu
SEK 17.88
rdh 52 mgu
SEK 0.90
EPS
-SEK 1.76
Syer tertunggak
134.00J
Bilangan pekerja
42
Cerita berita
Daripada sumber web dan rakan kongsi berita
BigGo Finance
·
12 jam lalu
Goldman Sachs Sets 8,700 S&P 500 Target for 2027, Sees 14% Upside as AI Capex Peaks
The Motley Fool
·
7 jam lalu
This Dividend King Yields 5 Times the S&P 500. Is It a Buy Now?
TradingView
·
17 jam lalu
Key facts: Tesla Merger Talks; $29,990 Cybercab Offer; S&P 500 Impact
StoneX
·
2 hari lalu
S&P 500, Nasdaq 100 Claw Back But NVDA Cloud Looms Overhead
Profil
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
Perihal Diamyd Medical AB